HNRNPUL1

Summary

HNRNPUL1 (heterogeneous nuclear ribonucleoprotein U like 1, HGNC:17011) is a protein-coding gene on chromosome 19q13.2, encoding Heterogeneous nuclear ribonucleoprotein U-like protein 1 (Q9BUJ2). Acts as a basic transcriptional regulator.

This gene encodes a nuclear RNA-binding protein of the heterogeneous nuclear ribonucleoprotein (hnRNP) family. This protein binds specifically to adenovirus early-1B-55kDa oncoprotein. It may play an important role in nucleocytoplasmic RNA transport, and its function is modulated by early-1B-55kDa in adenovirus-infected cells.

Source: NCBI Gene 11100 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 106 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_007040

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17011
Approved symbol	HNRNPUL1
Name	heterogeneous nuclear ribonucleoprotein U like 1
Location	19q13.2
Locus type	gene with protein product
Status	Approved
Aliases	E1B-AP5, E1BAP5, FLJ12944
Ensembl gene	ENSG00000105323
Ensembl biotype	protein_coding
OMIM	605800
Entrez	11100

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 15 protein_coding, 3 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000263367, ENST00000352456, ENST00000378215, ENST00000392006, ENST00000593587, ENST00000594207, ENST00000595018, ENST00000595196, ENST00000595336, ENST00000595806, ENST00000597725, ENST00000599521, ENST00000599614, ENST00000599719, ENST00000600332, ENST00000600493, ENST00000600596, ENST00000601309, ENST00000601336, ENST00000602130, ENST00000617774, ENST00000851914

RefSeq mRNA: 5 — MANE Select: NM_007040 NM_001301016, NM_001321208, NM_001321211, NM_007040, NM_144732

CCDS: CCDS12576, CCDS12577, CCDS82351

Canonical transcript exons

ENST00000392006 — 15 exons

Exon	Start	End
ENSE00002229704	41264372	41264798
ENSE00003128056	41306449	41307787
ENSE00003475476	41272082	41272235
ENSE00003503261	41276159	41276298
ENSE00003514719	41279077	41279176
ENSE00003526018	41268223	41268345
ENSE00003559428	41292245	41292511
ENSE00003585942	41273982	41274055
ENSE00003588424	41294558	41294686
ENSE00003634127	41305676	41305867
ENSE00003643382	41294338	41294460
ENSE00003647185	41303972	41304261
ENSE00003652933	41302665	41302949
ENSE00003658209	41301536	41301704
ENSE00003679215	41281163	41281275

Expression profiles

Bgee: expression breadth ubiquitous, 300 present calls, max score 98.75.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 116.1278 / max 647.0419, expressed in 1827 samples.

FANTOM5 promoters (31 alternative TSS)

Promoter ID	TPM avg	Samples expressed
175968	62.5525	1821
175967	19.0552	1811
175974	5.8487	1562
175996	3.5370	1456
175969	3.4762	1490
175964	2.4849	1169
175954	2.1826	1074
175986	1.2708	866
175976	1.2350	761
175966	1.2225	828

Top tissues by expression

300 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	98.75	gold quality
ganglionic eminence	UBERON:0004023	98.71	gold quality
sural nerve	UBERON:0015488	98.24	gold quality
cortical plate	UBERON:0005343	98.09	gold quality
mucosa of stomach	UBERON:0001199	97.76	gold quality
left ovary	UBERON:0002119	97.74	gold quality
stromal cell of endometrium	CL:0002255	97.50	gold quality
right ovary	UBERON:0002118	97.46	gold quality
bone marrow cell	CL:0002092	97.41	gold quality
body of uterus	UBERON:0009853	97.38	gold quality
endocervix	UBERON:0000458	97.34	gold quality
popliteal artery	UBERON:0002250	97.34	gold quality
tibial artery	UBERON:0007610	97.34	gold quality
monocyte	CL:0000576	97.32	gold quality
leukocyte	CL:0000738	97.29	gold quality
mononuclear cell	CL:0000842	97.26	gold quality
left uterine tube	UBERON:0001303	97.25	gold quality
skin of leg	UBERON:0001511	97.25	gold quality
ectocervix	UBERON:0012249	97.19	gold quality
granulocyte	CL:0000094	97.17	gold quality
right lung	UBERON:0002167	97.17	gold quality
calcaneal tendon	UBERON:0003701	97.16	gold quality
muscle layer of sigmoid colon	UBERON:0035805	97.16	gold quality
right coronary artery	UBERON:0001625	97.12	gold quality
colonic epithelium	UBERON:0000397	97.11	gold quality
lower esophagus	UBERON:0013473	97.10	gold quality
lower esophagus muscularis layer	UBERON:0035833	97.10	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	97.04	gold quality
skin of abdomen	UBERON:0001416	96.96	gold quality
lymph node	UBERON:0000029	96.92	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-8142	yes	80.32
E-CURD-88	yes	20.81
E-ANND-3	yes	11.65
E-CURD-135	no	842.69
E-HCAD-8	no	391.84
E-MTAB-7008	no	217.50
E-MTAB-6524	no	94.15

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MYC, TP53

miRNA regulators (miRDB)

79 targeting HNRNPUL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-4446-5P	99.72	69.19	2544
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-519A-3P	99.67	71.67	1868
HSA-MIR-519B-3P	99.67	71.67	1868
HSA-MIR-519C-3P	99.67	71.67	1870
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-671-5P	99.52	67.11	1277
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-516A-3P	99.46	67.96	1378

Literature-anchored findings (GeneRIF, showing 14)

• Regulation of transcripton by this protein is mediated by complex formation with BRD7 (PMID:12489984)
• Variants in 2 genes were associated with early-onset myocardial infarct: VAMP8, which is involved in platelet degranulation, and HNRPUL1, which encodes a ribonuclear protein. (PMID:16690874)
• Taken together, these results define a role for E1B-AP5 in ATR signaling pathways activated during adenovirus infection. (PMID:18480432)
• E1B-AP5 is a novel surface molecule that is involved in the undifferentiated state of human embryonic stem cells (PMID:21083500)
• hnRNPUL1 and -2 function downstream of MRN and CtBP-interacting protein (CtIP) to promote recruitment of the BLM helicase to DNA breaks. (PMID:22365830)
• U7 snRNP represses histone gene transcription under cell cycle-arrested conditions. hnRNP UL1 is responsible for U7 snRNP-dependent transcriptional repression of replication-dependent histone genes. (PMID:22451911)
• hnRPUL1 as a new component related to PARP1 in DNA damage response and repair (PMID:23577092)
• Despite the limitations, hnRPUL1 and PARP1 were downregulated in renal cell carcinoma and connected with the prognosis. (PMID:24595077)
• we define the arginines within the RGG/RG motifs as the site of methylation by PRMT1 both in vitro and in vivo. The arginines within the human hnRNPUL1 RGG/RG motifs were substituted with lysines to generate hnRNPUL1(RK). (PMID:26020839)
• Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. (PMID:32561361)
• HNRNPUL1 inhibits cisplatin sensitivity of esophageal squamous cell carcinoma through regulating the formation of circMAN1A2. (PMID:34688610)
• RNA-binding protein hnRNP UL1 binds kappaB sites to attenuate NF-kappaB-mediated inflammation. (PMID:35429914)
• The Novel Role of hnRNP UL1 in Human Cell Nucleoli. (PMID:35982897)
• Human E1B-AP5 binds to adenovirus E1B-55kDa protein. (PMID:9733834)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Hnrnpul1	ENSMUSG00000040725
rattus_norvegicus	Hnrnpul1	ENSRNOG00000020683

Paralogs (2): HNRNPU (ENSG00000153187), HNRNPUL2 (ENSG00000214753)

Protein

Protein identifiers

Heterogeneous nuclear ribonucleoprotein U-like protein 1 — Q9BUJ2 (reviewed: Q9BUJ2)

Alternative names: Adenovirus early region 1B-associated protein 5, E1B-55 kDa-associated protein 5

All UniProt accessions (13): Q9BUJ2, A0A087X1I2, A0A0A0MRA5, B7Z4B8, M0QYG9, M0QYI8, M0QYM5, M0QYZ0, M0QZV6, M0R0K8, M0R203, M0R247, M0R3F1

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a basic transcriptional regulator. Represses basic transcription driven by several virus and cellular promoters. When associated with BRD7, activates transcription of glucocorticoid-responsive promoter in the absence of ligand-stimulation. Also plays a role in mRNA processing and transport. Binds avidly to poly(G) and poly(C) RNA homopolymers in vitro.

Subunit / interactions. Interacts with the adenovirus type 5 (Ad5) E1B-55 kDa, BRD7, PRMT2, TP53 and NXF1. Associates with histones and BRD7.

Subcellular location. Nucleus.

Post-translational modifications. Methylated.

Domain organisation. The RGG-box domain is methylated.

Miscellaneous. Its methylation is enhanced in the late phase of adenoviral infection. May be due to intron retention.

Isoforms (5)

UniProt ID	Names	Canonical?
Q9BUJ2-1	1, Isoform a	yes
Q9BUJ2-2	2, Isoform b
Q9BUJ2-3	3
Q9BUJ2-4	4
Q9BUJ2-5	5

RefSeq proteins (5): NP_001287945, NP_001308137, NP_001308140, NP_008971, NP_653333 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001870	B30.2/SPRY	Domain
IPR003034	SAP_dom	Domain
IPR003877	SPRY_dom	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR035778	SPRY_hnRNP_U	Domain
IPR036361	SAP_dom_sf	Homologous_superfamily
IPR043136	B30.2/SPRY_sf	Homologous_superfamily

Pfam: PF00622, PF02037, PF13671

UniProt features (67 total): compositionally biased region 14, modified residue 11, cross-link 9, region of interest 7, splice variant 7, sequence conflict 7, repeat 5, helix 3, domain 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1ZRJ	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BUJ2-F1	66.66	0.41

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (20): 194, 209, 512, 639, 645, 645, 656, 656, 661, 671, 718, 117, 117, 142, 142, 146, 162, 270, 449, 539

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9918481	Dengue Virus-Host Interactions

MSigDB gene sets: 241 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, E2F_Q4, AGGAAGC_MIR5163P, E2F4DP1_01, GOBP_ALTERNATIVE_MRNA_SPLICING_VIA_SPLICEOSOME, MORF_SNRP70, MORF_UBE2I, MORF_HDAC1, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN, ATGCAGT_MIR217, MAYBURD_RESPONSE_TO_L663536_UP, MORF_TERF1, MORF_SKP1A, CATRRAGC_UNKNOWN, E2F1DP1_01

GO Biological Process (3): alternative mRNA splicing, via spliceosome (GO:0000380), RNA processing (GO:0006396), response to virus (GO:0009615)

GO Molecular Function (3): RNA binding (GO:0003723), enzyme binding (GO:0019899), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), synapse (GO:0045202), ribonucleoprotein complex (GO:1990904)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Dengue Virus Infection	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
mRNA splicing, via spliceosome	1
gene expression	1
RNA biosynthetic process	1
primary metabolic process	1
response to other organism	1
nucleic acid binding	1
protein binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
cell junction	1
protein-containing complex	1

Protein interactions and networks

STRING

1642 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HNRNPUL1	NXF1	Q9UBU9	989
HNRNPUL1	NXT1	Q9UKK6	895
HNRNPUL1	RAE1	P78406	887
HNRNPUL1	BRCA1	P38398	801
HNRNPUL1	NUTF2	P13662	702
HNRNPUL1	HNRNPM	P52272	687
HNRNPUL1	NUP62	P37198	686
HNRNPUL1	NUP98	P52948	666
HNRNPUL1	NXT2	Q9NPJ8	650
HNRNPUL1	NXF3	Q9H4D5	648
HNRNPUL1	NUP153	P49790	642
HNRNPUL1	HNRNPH1	P31943	619
HNRNPUL1	RBMX	P38159	613
HNRNPUL1	NUP214	P35658	593
HNRNPUL1	HNRNPC	P07910	591
HNRNPUL1	UIMC1	Q96RL1	591

IntAct

277 interactions, top by confidence:

A	B	Type	Score
WWP2	HNRNPUL1	psi-mi:“MI:0915”(physical association)	0.870
HNRNPUL1	WWP2	psi-mi:“MI:0915”(physical association)	0.870
YWHAB	PIK3C2A	psi-mi:“MI:0914”(association)	0.800
HNRNPUL1	DZIP3	psi-mi:“MI:0915”(physical association)	0.780
DZIP3	HNRNPUL1	psi-mi:“MI:0915”(physical association)	0.780
HNRNPUL1	HNRNPF	psi-mi:“MI:0915”(physical association)	0.740
HNRNPUL1	SF3B4	psi-mi:“MI:0915”(physical association)	0.740
HNRNPF	HNRNPUL1	psi-mi:“MI:0915”(physical association)	0.740
SF3B4	HNRNPUL1	psi-mi:“MI:0915”(physical association)	0.740
ETV6	LRP6	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
HNRNPUL1	TP53	psi-mi:“MI:0915”(physical association)	0.700
TP53	HNRNPUL1	psi-mi:“MI:0915”(physical association)	0.700

BioGRID (473): HNRNPUL1 (Two-hybrid), HNRNPUL1 (Two-hybrid), HNRNPUL1 (Two-hybrid), HNRNPUL1 (Two-hybrid), HNRNPUL1 (Two-hybrid), HNRNPUL1 (Two-hybrid), HNRNPUL1 (Two-hybrid), HNRNPUL1 (Two-hybrid), ROPN1 (Two-hybrid), VPS37C (Two-hybrid), RBM4B (Two-hybrid), MAPK1IP1L (Two-hybrid), HNRNPUL1 (Affinity Capture-MS), HNRNPUL1 (Affinity Capture-MS), HNRNPUL1 (Affinity Capture-MS)

ESM2 similar proteins: A0A3B3IU46, A0JMU8, A1L1K8, A2RV70, O94432, P07733, P45978, P46553, P90897, Q09801, Q09911, Q14444, Q1LZB6, Q24669, Q28F29, Q28HC9, Q2HJG4, Q5CZI8, Q5JVS0, Q5M9G3, Q5R9Q6, Q5UR41, Q5ZMS6, Q60865, Q66HC1, Q6CVS3, Q6FJC7, Q6NRP6, Q6NRY1, Q6NYG6, Q6P0F4, Q6P1U3, Q75A59, Q8CGZ0, Q8IWX8, Q8TAP9, Q8VDM6, Q91W18, Q9BTL3, Q9BUJ2

Diamond homologs: Q00839, Q00PI9, Q1KMD3, Q55CP6, Q6IMY8, Q8VDM6, Q8VEK3, Q9BUJ2, Q9VNV3, A2VD92, P53076, Q0IIK5, Q19614, Q4R7L5, Q5NVJ8, Q5XH91, Q641Y8, Q90WU3, Q91VR5, Q92499, A0A5F9C6I2, A1L252, A3KMV8, B0LPN4, D3ZXK7, E9PZQ0, E9Q401, O94712, P11716, P16960, P21817, P30957, P69566, Q15413, Q1LUS8, Q24498, Q28FM1, Q5XPI3, Q6VN19, Q6VN20

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 179 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	37.0×	8e-08
Activation of BAD and translocation to mitochondria	6	36.0×	8e-07
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	6	31.7×	2e-06
Activation of BH3-only proteins	8	31.3×	6e-08
Intrinsic Pathway for Apoptosis	9	20.8×	8e-08
RHO GTPases activate PKNs	6	15.0×	1e-04
Apoptosis	10	13.2×	4e-07
FOXO-mediated transcription	5	13.2×	9e-04

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of innate immune response	6	19.1×	2e-04
intrinsic apoptotic signaling pathway	7	15.7×	1e-04
autophagosome maturation	6	13.2×	9e-04
protein targeting	5	11.4×	8e-03
intracellular protein localization	10	6.5×	6e-04
RNA splicing	9	5.0×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

106 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	76
Likely benign	1
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2336 predictions. Top by Δscore:

Variant	Effect	Δscore
19:41264690:G:GT	donor_gain	1.0000
19:41268220:A:AG	acceptor_gain	1.0000
19:41268220:AAG:A	acceptor_loss	1.0000
19:41268220:AAGAT:A	acceptor_gain	1.0000
19:41268221:A:AG	acceptor_gain	1.0000
19:41268221:AGA:A	acceptor_loss	1.0000
19:41268221:AGAT:A	acceptor_gain	1.0000
19:41268222:G:GA	acceptor_gain	1.0000
19:41268222:GA:G	acceptor_gain	1.0000
19:41268222:GAT:G	acceptor_gain	1.0000
19:41268222:GATG:G	acceptor_gain	1.0000
19:41268222:GATGC:G	acceptor_gain	1.0000
19:41268342:CCAG:C	donor_loss	1.0000
19:41268343:CAGGT:C	donor_loss	1.0000
19:41268344:AGG:A	donor_loss	1.0000
19:41268345:GGT:G	donor_loss	1.0000
19:41268346:GTAGG:G	donor_loss	1.0000
19:41268347:T:A	donor_loss	1.0000
19:41272077:A:AG	acceptor_gain	1.0000
19:41272182:GCCT:G	donor_gain	1.0000
19:41274051:CACCT:C	donor_gain	1.0000
19:41274052:ACCT:A	donor_gain	1.0000
19:41274053:CCT:C	donor_gain	1.0000
19:41274056:G:GG	donor_gain	1.0000
19:41279075:A:AG	acceptor_gain	1.0000
19:41279075:A:AT	acceptor_loss	1.0000
19:41279076:G:A	acceptor_loss	1.0000
19:41279076:G:GA	acceptor_gain	1.0000
19:41279076:GAT:G	acceptor_gain	1.0000
19:41279076:GATC:G	acceptor_gain	1.0000

AlphaMissense

5616 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:41264520:T:C	L6P	1.000
19:41264525:G:A	V8M	1.000
19:41264535:T:A	L11H	1.000
19:41264535:T:C	L11P	1.000
19:41264537:C:A	R12S	1.000
19:41264547:T:A	L15Q	1.000
19:41264547:T:C	L15P	1.000
19:41264556:G:C	R18P	1.000
19:41264562:T:C	L20P	1.000
19:41264573:G:C	G24R	1.000
19:41264574:G:A	G24D	1.000
19:41264581:G:C	K26N	1.000
19:41264581:G:T	K26N	1.000
19:41264589:T:A	L29H	1.000
19:41264589:T:C	L29P	1.000
19:41264598:G:C	R32P	1.000
19:41264601:T:C	L33P	1.000
19:41276168:A:T	D219V	1.000
19:41276177:T:C	F222S	1.000
19:41276203:G:C	G231R	1.000
19:41276204:G:A	G231D	1.000
19:41276210:C:A	P233Q	1.000
19:41276210:C:G	P233R	1.000
19:41276213:T:A	L234H	1.000
19:41276213:T:C	L234P	1.000
19:41276224:G:C	G238R	1.000
19:41276225:G:A	G238D	1.000
19:41276227:T:A	F239I	1.000
19:41276227:T:C	F239L	1.000
19:41276227:T:G	F239V	1.000

dbSNP variants (sampled 300 via entrez): RS1000072986 (19:41261862 C>A), RS1000089279 (19:41303213 C>T), RS1000104818 (19:41292943 C>G), RS1000124895 (19:41262078 T>C), RS1000157054 (19:41273903 A>G), RS1000225350 (19:41270677 C>T), RS1000254518 (19:41267505 C>T), RS1000331310 (19:41280002 C>A,G), RS1000365900 (19:41287368 A>G), RS1000376119 (19:41287086 G>A), RS1000423274 (19:41299515 G>A), RS1000440242 (19:41273570 G>A), RS1000492102 (19:41272299 T>G), RS1000544708 (19:41303427 C>G,T), RS1000576133 (19:41276967 G>A)

Disease associations

OMIM: gene MIM:605800 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST006288_674	Heel bone mineral density	9.000000e-11
GCST006288_74	Heel bone mineral density	4.000000e-10
GCST008790_57	Urinary albumin-to-creatinine ratio	2.000000e-10
GCST008794_10	Urinary albumin-to-creatinine ratio	2.000000e-10
GCST008794_9	Urinary albumin-to-creatinine ratio	3.000000e-08
GCST010241_355	Apolipoprotein A1 levels	4.000000e-11
GCST010242_365	HDL cholesterol levels	2.000000e-10

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0009270	heel bone mineral density
EFO:0007778	urinary albumin to creatinine ratio
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004612	high density lipoprotein cholesterol measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724663 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1056854	HNRNPUL1	3	0.00	1	glatiramer acetate

ChEMBL bioactivities

5 potent at pChembl≥5 of 5 total, top 5 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.75	IC50	180	nM	MOLIBRESIB
6.04	Kd	921.9	nM	CHEMBL3752910
6.04	ED50	921.9	nM	CHEMBL3752910
5.59	Kd	2560	nM	CHEMBL5653589
5.59	ED50	2560	nM	CHEMBL5653589

PubChem BioAssay actives

3 with measured affinity, of 10 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178569: Inhibition of HNRNPUL1 (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	0.1800	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148539: Binding affinity to human HNRNPUL1 incubated for 45 mins by Kinobead based pull down assay	kd	0.9219	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148539: Binding affinity to human HNRNPUL1 incubated for 45 mins by Kinobead based pull down assay	kd	2.5599	uM

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, decreases methylation, increases expression	3
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
bisphenol F	increases expression	1
TAK-243	decreases sumoylation	1
dicrotophos	increases expression	1
2,4,6-tribromophenol	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
deoxynivalenol	increases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, increases expression	1
arsenite	affects binding, decreases reaction	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
pyrrolidine dithiocarbamic acid	affects cotreatment, increases expression	1
bathocuproine sulfonate	affects cotreatment, increases expression	1
coumarin	increases phosphorylation	1
methacrylaldehyde	increases oxidation, increases abundance, affects cotreatment	1
2,3,5-(triglutathion-S-yl)hydroquinone	decreases ADP-ribosylation	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
nutlin 3	affects cotreatment, increases secretion	1
bisphenol B	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
bisphenol S	increases expression	1
LDN 193189	affects cotreatment, increases expression	1
NSC 689534	affects binding, decreases expression	1
bisphenol AF	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Acetaminophen	decreases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651581	Binding	Binding affinity to human HNRNPUL1 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

5 cell lines: 4 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1374	LC4-1	Cancer cell line	Female
CVCL_1631	P30/OHK	Cancer cell line	Female
CVCL_8486	Kasumi-7	Cancer cell line	Female
CVCL_8488	Kasumi-9	Cancer cell line	Male
CVCL_B2Z3	Abcam HEK293T HNRNPUL1 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.